Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network. [electronic resource]
Producer: 19931228Description: 1387-95 p. digitalISSN:- 0022-1899
- AIDS Vaccines -- administration & dosage
- Adjuvants, Immunologic
- Adolescent
- Adult
- Aged
- Animals
- Antibodies, Antinuclear -- immunology
- Cells, Cultured
- Double-Blind Method
- Female
- Gene Products, env -- adverse effects
- Glycosylation
- HIV Envelope Protein gp160
- HIV-1 -- immunology
- Humans
- Lymphocytes -- immunology
- Male
- Middle Aged
- Protein Precursors -- adverse effects
- Safety
- Vaccines, Synthetic -- administration & dosage
- Vero Cells
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.